Peter Lin MD, CCFP
Director, Primary Care Initiatives, Canadian Heart Research Centre, North York, OntarioDr. Peter Lin, a primary care physician, is the Director of Primary Care Initiatives at the Canadian Heart Research Centre and has two busy family medicine practices in Toronto. For 7 years, he served as the medical director at the University of Toronto Scarborough Health & Wellness Centre. In 2011, he received a teaching award from the College of Family Physicians of Canada.
Dr. Lin has worked with KDIGO (Kidney Disease│Improving Global Outcomes) in an effort to help enhance care for patients with chronic kidney disease. He has been a contributing author to the Canadian Diabetes Guidelines and has served on the editorial board of Pri-Med Institute, which provides education for physicians.
Dr. Lin maintains an active lecture schedule, reflecting his varied medical interests, continuing his focus on bridging the chasm between research and clinical practice.
Disclosures
- Consultant (continuing medical education programs): AstraZeneca; Boehringer Ingelheim; Bayer; Eli Lilly; Amgen; Janssen; Merck; Pfizer; Sanofi; Abbott; HLS Therapeutics
Recent Contributions to PracticeUpdate:
- Dupilumab for Patients With COPD With Type 2 Inflammation Indicated by Eosinophil Counts
- Association of Exposure to Extreme Temperature Events and Fine Particulate Matter With Myocardial Infarction–Related Mortality
- Association Between Serum 25-Hydroxyvitamin D Levels and the Risk of Colorectal Cancer
- Protective Effect of HDL-C Against Cardiovascular Disease
- Safety and Effectiveness of Self-Administered Intranasal Etripamil for Atrioventricular Nodal–Dependent Supraventricular Tachycardia
- Topical Esmolol Hydrochloride as a Novel Treatment Modality for Diabetic Foot Ulcers
- Association of Statin Initiation With the Risk of Incident Kidney Disease in Patients With Diabetes
- Sulfonylureas as Second-Line Drugs for Cardiovascular Safety in Type 2 Diabetes
- Association of Sulfonylureas With the Risk of Dementia
- Primary Occurrence of Cardiovascular Events in Veterans With Diabetes After Adding SGLT2 Inhibitors or GLP-1 Receptor Agonists Compared With DPP-4 Inhibitors